ACRS · Aclaris Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.83M | $18.72M | $31.25M | $29.75M | $6.76M | $6.48M |
| Cost of Revenue | $2.09M | $2.79M | $3.42M | $4.02M | $4.71M | $5.13M |
| Gross Profit | $5.74M | $15.93M | $27.83M | $25.73M | $2.05M | $1.35M |
| R&D | $52.65M | $33.59M | $98.38M | $77.81M | $43.81M | $31.73M |
| SG&A | $21.97M | $22.20M | $32.41M | $25.13M | $23.62M | $20.53M |
| Total Operating Expenses | $84.20M | $160.65M | $128.61M | $119.61M | $96.48M | $57.39M |
| D&A | $454.0K | $807.0K | $863.0K | $797.0K | $923.0K | $1.32M |
| Operating Income | ($76.38M) | ($141.93M) | ($97.36M) | ($89.85M) | ($89.72M) | ($50.91M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | ($367.0K) | - | - | ($182.0K) |
| Net Income | ($64.92M) | ($132.06M) | ($88.48M) | ($86.91M) | ($90.86M) | ($51.02M) |
| EPS - Basic | ($0.53) | ($1.71) | ($1.27) | ($1.33) | ($1.20) | - |
| EPS - Diluted | ($0.53) | ($1.71) | ($1.27) | ($1.33) | ($1.20) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.96M | $24.57M | $39.88M | $45.28M | $27.35M | $22.06M |
| Accounts Receivable | - | $318.0K | $298.0K | $484.0K | $623.0K | $772.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $13.16M | $4.69M | $8.88M | $10.35M | $9.98M | $5.25M |
| Current Assets | $96.32M | $125.95M | $128.86M | $231.55M | $205.03M | $57.49M |
| Total Assets | $160.46M | $220.33M | $197.41M | $254.60M | $251.21M | $70.78M |
| Current Liabilities | $28.64M | $31.60M | $30.95M | $21.94M | $22.93M | $14.87M |
| Long-term Debt | - | - | - | - | - | $10.65M |
| Total Liabilities | $57.38M | $64.77M | $40.23M | $56.98M | $53.87M | $33.13M |
| Stockholders' Equity | $103.08M | $155.55M | $157.18M | $197.62M | $197.34M | $37.65M |
| Retained Earnings | ($967.78M) | ($902.86M) | ($770.80M) | ($682.32M) | ($595.41M) | ($504.54M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($47.11M) | ($20.07M) | ($78.33M) | ($67.57M) | ($52.13M) | ($38.63M) |
| Investing Cash Flow | $48.37M | ($69.77M) | $46.22M | $12.63M | ($167.63M) | $6.39M |
| Financing Cash Flow | ($5.86M) | $74.54M | $26.71M | $72.87M | $225.05M | $18.37M |
| CapEx | $111.0K | $121.0K | $1.31M | $605.0K | $308.0K | $453.0K |
| Free Cash Flow | ($47.22M) | ($20.20M) | ($79.63M) | ($68.17M) | ($52.44M) | ($39.09M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 73.3% | 85.1% | 89.0% | 86.5% | 30.3% | 20.8% |
| Operating margin | -975.9% | -758.2% | -311.6% | -302.0% | -1327.1% | -785.4% |
| EBITDA margin | -970.1% | -753.9% | -308.8% | -299.3% | -1313.4% | -765.0% |
| Net margin | -829.6% | -705.5% | -283.1% | -292.1% | -1344.0% | -787.0% |
| Free cash flow margin | -603.4% | -107.9% | -254.8% | -229.1% | -775.7% | -603.0% |
| FCF / Net income | 0.73 | 0.15 | 0.90 | 0.78 | 0.58 | 0.77 |
| R&D / Revenue | 672.7% | 179.4% | 314.8% | 261.5% | 648.0% | 489.5% |
| SG&A / Revenue | 280.8% | 118.6% | 103.7% | 84.5% | 349.3% | 316.7% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -40.5% | -59.9% | -44.8% | -34.1% | -36.2% | -72.1% |
| Return on equity | -63.0% | -84.9% | -56.3% | -44.0% | -46.0% | -135.5% |
| Return on invested capital | - | - | - | - | - | -83.3% |
| Liquidity | ||||||
| Current ratio | 3.36 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 |
| Quick ratio | 3.36 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 |
| Cash ratio | 0.70 | 0.78 | 1.29 | 2.06 | 1.19 | 1.48 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | 0.28 |
| Debt / Assets | - | - | - | - | - | 0.15 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.56 | 1.42 | 1.26 | 1.29 | 1.27 | 1.88 |
| Liabilities / Assets | 0.36 | 0.29 | 0.20 | 0.22 | 0.21 | 0.47 |
| Efficiency | ||||||
| Asset turnover | 0.05 | 0.08 | 0.16 | 0.12 | 0.03 | 0.09 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | 6d | 3d | 6d | 34d | 43d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 2297d | 613d | 947d | 939d | 773d | 374d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 3.6x | 1.2x | 0.5x | 5.2x | 3.1x | - |
| P / S | 47.1x | 10.2x | 2.3x | 34.5x | 91.5x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -58.2% | -40.1% | 5.0% | 340.1% | 4.3% | 53.3% |
| Revenue CAGR (3y) | -35.9% | 40.4% | 68.9% | 91.6% | 59.0% | 56.8% |
| Revenue CAGR (5y) | 3.8% | 34.7% | 79.4% | 77.6% | - | - |
| Gross profit growth (YoY) | -64.0% | -42.8% | 8.2% | 1156.3% | 51.8% | 684.3% |
| Operating income growth (YoY) | 46.2% | -45.8% | -8.4% | -0.1% | -76.2% | 54.2% |
| Net income growth (YoY) | 50.8% | -49.3% | -1.8% | 4.4% | -78.1% | 68.4% |
| EPS growth (YoY) | 69.0% | -34.6% | 4.5% | -10.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -133.8% | 74.6% | -16.8% | -30.0% | -34.2% | 60.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -33.7% | -1.0% | -20.5% | 0.1% | 424.1% | -46.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$7.83M totalSingle Reportable Segment$7.83M · 100.0%
Product / service
$15.65M totalDermatology Therapeutics Segment$5.95M · 38.0%
License And Service$5.95M · 38.0%
Contract Research Segment$1.87M · 12.0%
Laboratory Research Revenue$1.87M · 12.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-5.48
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Aclaris Therapeutics against the 5 most active filers in the same SIC group.